Later is greater.
This new pooled analysis of RTOG 9413 and this Canadian trial compared all enrollees receiving 6 months of androgen deprivation therapy (ADT) either neoadjuvant (n=531) or adjuvant (n=534) to prostate-only radiation. In short, adjuvant ADT won in all regards. At 15 years, it resulted in lower rates of biochemical failure (33% vs 43%) and mets (12% vs 18%) and higher progression-free survival (36% vs 29%). It also significantly improved chances of not dying from high-risk prostate cancer (HR 1.39). | Spratt, ASTRO 2020